Guggenheim analyst Seamus Fernandez raised the firm's price target on Amylyx to $30 from $25 and keeps a Buy rating on the shares based on "high confidence" in a positive LUCIDITY readout with topline data confirmed to be coming in Q3. Data from LUCIDITY could establish avexitide as the first-ever FDA approved treatment for 150,000-plus postbariatric hypoglycemia patients in the U.S., the analyst tells investors.
